@Article{,
AUTHOR = {Andrew J. Armstrong, Michael A. Carducci},
TITLE = {Advanced prostate cancer: the future},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {12},
YEAR = {2005},
NUMBER = {Suppl.3},
PAGES = {42--47},
URL = {http://www.techscience.com/CJU/v12nSuppl.3/63369},
ISSN = {1488-5581},
ABSTRACT = {The demonstration of a survival benefit with docetaxel
for the treatment of metastatic hormone refractory
prostate cancer (HRPC) is an important step forward in
advancing treatment options for advanced prostate
cancer. While docetaxel-based therapy has demonstrated
improvement in symptomatic and quality-of-life
endpoints, certainly there is a pressing need for improvement in outcomes. A number of novel agents
are in basic and clinical development for advanced
prostate cancer, some of which are specific to mechanisms
that may be important in the development and spread of
prostate cancer. Novel approaches including novel
cytotoxics, immunotherapy, PSMA targeted monoclonal
antibodies are among the broad categories that will be
discussed in this brief review.},
DOI = {}
}